相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Biomarkers of angiogenesis and their role in the development of VEGF inhibitors
N. Murukesh et al.
BRITISH JOURNAL OF CANCER (2010)
Plasma Cytokine and Angiogenic Factor Profiling Identifies Markers Associated with Tumor Shrinkage in Early-Stage Non-Small Cell Lung Cancer Patients Treated with Pazopanib
Petros G. Nikolinakos et al.
CANCER RESEARCH (2010)
Biomarkers as Predictors of Response to Treatment with Motesanib in Patients with Progressive Advanced Thyroid Cancer
Michael B. Bass et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2010)
Distinct Patterns of Cytokine and Angiogenic Factor Modulation and Markers of Benefit for Vandetanib and/or Chemotherapy in Patients With Non-Small-Cell Lung Cancer
Emer O. Hanrahan et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
(Pre-)Clinical Pharmacology and Activity of Pazopanib, a Novel Multikinase Angiogenesis Inhibitor
Paul Hamberg et al.
ONCOLOGIST (2010)
Baseline Vascular Endothelial Growth Factor Concentration as a Potential Predictive Marker of Benefit from Vandetanib in Non-Small Cell Lung Cancer
Emer O. Hanrahan et al.
CLINICAL CANCER RESEARCH (2009)
Efficacy and Safety of Trabectedin in Patients With Advanced or Metastatic Liposarcoma or Leiomyosarcoma After Failure of Prior Anthracyclines and Ifosfamide: Results of a Randomized Phase II Study of Two Different Schedules
George D. Demetri et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC Study 62043)
Stefan Sleijfer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
Brian I. Rini et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
A randomized, bouble-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with nonsmall cell lung cancer
Katsuyuki Kiura et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy?
Christian Fischer et al.
NATURE REVIEWS CANCER (2008)
Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy
John M. L. Ebos et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Two phase 1 studies of MPC-6827, a novel vascular disrupting agent (VDA), in patients with advanced solid tumors and CNS metastases
R. Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors
Lee S. Rosen et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
The pharmacologic basis of ifosfamide use in adult patients with advanced soft tissue sarcomas
Metin Tascilar et al.
ONCOLOGIST (2007)
Using single-agent therapy in adult patients with advanced soft tissue sarcoma can still be considered standard care
S Sleijfer et al.
ONCOLOGIST (2005)
Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials
J Drevs et al.
ANNALS OF ONCOLOGY (2005)
Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial
J Verweij et al.
LANCET (2004)
分享论文
